Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Quest Diagnostics (DGX)

NYSE: DGX · Health Care Services · Secaucus, NJ

Our rating: Neutral

Neutral reaffirmed at $242.95, moderate conviction, October 26, 2026.

Breaks if: This Neutral view flips to Positive if revenue growth holds at or above 8% year-over-year for two consecutive quarterly filings while net margin expands above 10.0%, confirming that the current growth rate is durable and beginning to drive operating leverage. It flips to Cautious if revenue growth decelerates below 3% year-over-year, or if net margin slips below 7.5% in any two of the next three quarterly filings — either outcome would mean the 27.8x P/E is pricing in a business trajectory that no longer exists.

Key figures

Market value$28.4B
Revenue, last 12 months$11.8B
Net income, last 12 months$1.1B
Free cash flow, last 12 months$1.4B
Price to earnings25.2×
Free cash flow yield4.8%
Dividend yield1.3%
Operating margin14.6%
Return on equity15.2%
Beta to the S&P 5000.16
Volatility, annualized22.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$3.1B10.0%$2.78$445M
June 30, 2026$3.0B10.2%$2.84$459M
March 31, 2026$2.9B9.2%$2.24$164M
December 31, 2025$2.8B7.1%$2.18$307M
September 30, 2025$2.8B13.2%$2.16$419M
June 30, 2025$2.8B15.2%$2.47$436M
March 31, 2025$2.7B12.1%$1.94$197M
December 31, 2024$2.6B14.6%$1.95$341M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

13 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.